Close Menu

NEW YORK – Guardant Health reported after the close of the market on Thursday that its first quarter 2019 revenues were up 84 percent year over year.

The liquid biopsy firm reported total revenues of $67.5 million compared to $36.7 million in Q1 2019, easily beating the consensus Wall Street estimate of $56.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.